Literature DB >> 33975093

Specialty knowledge and competency standards for pharmacotherapy for adult obsessive-compulsive disorder.

Christopher Pittenger1, Brian P Brennan2, Lorrin Koran3, Carol A Mathews4, Gerald Nestadt5, Michele Pato6, Katharine A Phillips7, Carolyn I Rodriguez8, H Blair Simpson9, Petros Skapinakis10, Dan J Stein11, Eric A Storch12.   

Abstract

Obsessive-compulsive disorder (OCD) affects approximately one person in 40 and causes substantial suffering. Evidence-based treatments can benefit many; however, optimal treatment can be difficult to access. Diagnosis is frequently delayed, and pharmacological and psychotherapeutic interventions often fail to follow evidence-based guidelines. To ameliorate this distressing situation, the International OCD Accreditation Task Force of the Canadian Institute for Obsessive-Compulsive Disorders has developed knowledge and competency standards for specialized treatments for OCD through the lifespan. These are foundational to evidence-based practice and will form the basis for upcoming ATF development of certification/accreditation programs. Here, we present specialty standards for the pharmacological treatment of adult OCD. We emphasize the importance of integrating pharmacotherapy with clear diagnosis, appreciation of complicating factors, and evidence-based cognitive behavioral therapy. Clear evidence exists to inform first- and second-line pharmacological treatments. In disease refractory to these initial efforts, multiple strategies have been investigated, but the evidence is more equivocal. These standards summarize this limited evidence to give the specialist practitioner a solid basis on which to make difficult decisions in complex cases. It is hoped that further research will lead to development of a clear, multi-step treatment algorithm to support each step in clinical decision-making.
Copyright © 2021 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Obsessive-compulsive disorder (OCD); augmentation; comorbidity; pharmacotherapy; selective serotonin reuptake inhibitors (SSRIs); treatment

Mesh:

Substances:

Year:  2021        PMID: 33975093      PMCID: PMC8536398          DOI: 10.1016/j.psychres.2021.113853

Source DB:  PubMed          Journal:  Psychiatry Res        ISSN: 0165-1781            Impact factor:   11.225


  272 in total

Review 1.  Brain circuitry of compulsivity.

Authors:  Odile A van den Heuvel; Guido van Wingen; Carles Soriano-Mas; Pino Alonso; Samuel R Chamberlain; Takashi Nakamae; Damiaan Denys; Anna E Goudriaan; Dick J Veltman
Journal:  Eur Neuropsychopharmacol       Date:  2015-12-11       Impact factor: 4.600

2.  Multivariate meta-analysis of controlled drug studies for obsessive-compulsive disorder.

Authors:  Deborah L Ackerman; Sander Greenland
Journal:  J Clin Psychopharmacol       Date:  2002-06       Impact factor: 3.153

3.  N-Acetyl Cysteine (NAC) in the Treatment of Obsessive-Compulsive Disorder: A 16-Week, Double-Blind, Randomised, Placebo-Controlled Study.

Authors:  Jerome Sarris; Georgina Oliver; David A Camfield; Olivia M Dean; Nathan Dowling; Deidre J Smith; Jenifer Murphy; Ranjit Menon; Michael Berk; Scott Blair-West; Chee H Ng
Journal:  CNS Drugs       Date:  2015-09       Impact factor: 5.749

Review 4.  Are 5-HT3 antagonists effective in obsessive-compulsive disorder? A systematic review of literature.

Authors:  Daniele Serata; Georgios D Kotzalidis; Chiara Rapinesi; Delfina Janiri; Simone Di Pietro; Gemma Callovini; Daria Piacentino; Carlotta Gasperoni; Roberto Brugnoli; Vittoria Rachele Ferri; Nicoletta Girardi; Roberto Tatarelli; Stefano Ferracuti; Gloria Angeletti; Paolo Girardi; Antonio Del Casale
Journal:  Hum Psychopharmacol       Date:  2015-02-10       Impact factor: 1.672

Review 5.  Sleep and obsessive-compulsive disorder (OCD).

Authors:  Jessica L Paterson; Amy C Reynolds; Sally A Ferguson; Drew Dawson
Journal:  Sleep Med Rev       Date:  2013-03-14       Impact factor: 11.609

6.  Adjunctive glycine in the treatment of obsessive-compulsive disorder in adults.

Authors:  William M Greenberg; Melissa M Benedict; Joanna Doerfer; Megan Perrin; Laura Panek; W Louis Cleveland; Daniel C Javitt
Journal:  J Psychiatr Res       Date:  2008-11-30       Impact factor: 4.791

7.  N-acetylcysteine augmentation therapy for moderate-to-severe obsessive-compulsive disorder: randomized, double-blind, placebo-controlled trial.

Authors:  K Paydary; A Akamaloo; A Ahmadipour; F Pishgar; S Emamzadehfard; S Akhondzadeh
Journal:  J Clin Pharm Ther       Date:  2016-03-02       Impact factor: 2.512

Review 8.  Factors associated with non-treatment or delayed treatment seeking in OCD sufferers: a review of the literature.

Authors:  Gemma García-Soriano; Michael Rufer; Aba Delsignore; Steffi Weidt
Journal:  Psychiatry Res       Date:  2014-07-11       Impact factor: 3.222

Review 9.  Selective serotonin re-uptake inhibitors (SSRIs) versus placebo for obsessive compulsive disorder (OCD).

Authors:  G M Soomro; D Altman; S Rajagopal; M Oakley-Browne
Journal:  Cochrane Database Syst Rev       Date:  2008-01-23

Review 10.  Pharmacological and psychotherapeutic interventions for management of obsessive-compulsive disorder in adults: a systematic review and network meta-analysis.

Authors:  Petros Skapinakis; Deborah M Caldwell; William Hollingworth; Peter Bryden; Naomi A Fineberg; Paul Salkovskis; Nicky J Welton; Helen Baxter; David Kessler; Rachel Churchill; Glyn Lewis
Journal:  Lancet Psychiatry       Date:  2016-06-16       Impact factor: 27.083

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.